SynthesisFrontiers in oncology2025
Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pretransplant Systemic Therapies for Hepatocellular Carcinoma: A Systematic Review of Posttransplant Outcomes.Journal of gastrointestinal cancer · 2026Pooled it
- Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation.Journal of clinical medicine · 2026Review
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
- Balancing Tumor Response and Rejection Risk After Pre-Transplant Immunotherapy: A Scoping Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The administration of immune checkpoint inhibitors (ICIs) prior to liver transplantation (LT) for hepatocellular carcinoma (HCC) has been reported. Several studies suggest that ICIs may elevate the risk of allograft rejection (AR) and influence other clinical outcomes. This meta-analysis aimed to assess the efficacy and safety of pre-LT ICI treatment in HCC patients. Methods: A systematic literature search was conducted in PubMed, Embase, Cochrane, and Web of Science for retrospective studies and randomized controlled trials (RCTs) examining pre-LT ICI therapies in HCC patients. Random-effects models were employed to evaluate treatment effects on allograft rejection (AR), complete recovery rate among patients with AR, graft loss, HCC recurrence, and progression-free survival (PFS). Common-effects models were used to assess overall mortality and AR-related mortality. Study quality was evaluated using the JBI critical appraisal tools. The review was registered with PROSPERO (CRD42024616267). Results: Studies involving HCC patients receiving pre-LT ICIs for downstaging or bridging were included. After screening databases from inception to 31 December 2024, eight studies ( Conclusion: The use of ICIs as bridging or downstaging therapy prior to liver transplantation in HCC patients appears feasible. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024616267.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.